Part D
Part D
Ensuring a Robust Medicare Drug Benefit
Schaeffer researchers study Part D’s impact on formulary and benefit design, patient costs, innovation and overall health, with a focus on ensuring Medicare beneficiaries can access the high-value medications they need.
Related Topics
Top Stories View All
Perspective
Assessing the Case Against Direct-to-Consumer Drug Advertisements
Featured Experts: Neeraj Sood
In The News View All
Tradeoffs
Trish interviewed on rising Medicare drug plan costs and narrowing options
Featured Experts: Erin Trish
The Hill
CMS staffing shortages could make the Medicare enrollment season challenging for beneficiaries, Blum warns
STAT
Joyce explains why Trump could more easily use Medicare negotiations, rather than most-favored nation, to slash drug prices
Featured Experts: Geoffrey Joyce
Health Affairs
Lieberman discusses the meteoric rise of Medicare Advantage and possible reforms
Featured Experts: Steve M. Lieberman
POLITICO
“Most Favored Nation” could incentivize drugmakers to pull products overseas, hurting patients worldwide, Lakdawalla warns
Featured Experts: Darius Lakdawalla
Featured Research
Reforming the Medicare Part D Benefit Design: Financial Implications for Beneficiaries, Private Plans, Drug Manufacturers, and the Federal Government
Researchers evaluate prescription drug claims from Medicare Part D beneficiaries to evaluate the current spending distribution.
Experts: Erin Trish, Geoffrey Joyce